Logo image of MIST

MILESTONE PHARMACEUTICALS IN (MIST) Stock Fundamental Analysis

NASDAQ:MIST - Nasdaq - CA59935V1076 - Common Stock - Currency: USD

2.04  -0.02 (-0.97%)

After market: 2.146 +0.11 (+5.2%)

Fundamental Rating

2

MIST gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 193 industry peers in the Pharmaceuticals industry. MIST scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. MIST is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

MIST had negative earnings in the past year.
In the past year MIST has reported a negative cash flow from operations.
MIST had negative earnings in each of the past 5 years.
MIST had a negative operating cash flow in each of the past 5 years.
MIST Yearly Net Income VS EBIT VS OCF VS FCFMIST Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 -20M -40M -60M

1.2 Ratios

MIST has a Return On Assets of -51.71%. This is in the lower half of the industry: MIST underperforms 63.78% of its industry peers.
With a Return On Equity value of -178.11%, MIST is not doing good in the industry: 68.65% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -51.71%
ROE -178.11%
ROIC N/A
ROA(3y)-64.49%
ROA(5y)-54.31%
ROE(3y)-160.67%
ROE(5y)-113%
ROIC(3y)N/A
ROIC(5y)N/A
MIST Yearly ROA, ROE, ROICMIST Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 -100 -200 -300

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for MIST so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
MIST Yearly Profit, Operating, Gross MarginsMIST Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 -2K -4K -6K

More info and screens

4

2. Health

2.1 Basic Checks

MIST does not have a ROIC to compare to the WACC, probably because it is not profitable.
MIST has less shares outstanding than it did 1 year ago.
Compared to 5 years ago, MIST has more shares outstanding
The debt/assets ratio for MIST is higher compared to a year ago.
MIST Yearly Shares OutstandingMIST Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M
MIST Yearly Total Debt VS Total AssetsMIST Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 50M 100M

2.2 Solvency

Based on the Altman-Z score of -4.64, we must say that MIST is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of MIST (-4.64) is worse than 62.70% of its industry peers.
A Debt/Equity ratio of 2.18 is on the high side and indicates that MIST has dependencies on debt financing.
Looking at the Debt to Equity ratio, with a value of 2.18, MIST is doing worse than 80.00% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 2.18
Debt/FCF N/A
Altman-Z -4.64
ROIC/WACCN/A
WACC8.45%
MIST Yearly LT Debt VS Equity VS FCFMIST Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 0 50M -50M 100M

2.3 Liquidity

A Current Ratio of 15.40 indicates that MIST has no problem at all paying its short term obligations.
MIST has a better Current ratio (15.40) than 88.65% of its industry peers.
A Quick Ratio of 15.40 indicates that MIST has no problem at all paying its short term obligations.
The Quick ratio of MIST (15.40) is better than 88.65% of its industry peers.
Industry RankSector Rank
Current Ratio 15.4
Quick Ratio 15.4
MIST Yearly Current Assets VS Current LiabilitesMIST Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 50M 100M

More info and screens

4

3. Growth

3.1 Past

MIST shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 41.30%, which is quite impressive.
Looking at the last year, MIST shows a very negative growth in Revenue. The Revenue has decreased by -100.00% in the last year.
EPS 1Y (TTM)41.3%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%60%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

MIST is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 27.19% yearly.
Based on estimates for the next years, MIST will show a very strong growth in Revenue. The Revenue will grow by 200.41% on average per year.
EPS Next Y54.32%
EPS Next 2Y12.44%
EPS Next 3Y20.35%
EPS Next 5Y27.19%
Revenue Next Year-100%
Revenue Next 2Y114.48%
Revenue Next 3Y281.33%
Revenue Next 5Y200.41%

3.3 Evolution

MIST Yearly Revenue VS EstimatesMIST Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 100M 200M 300M 400M 500M
MIST Yearly EPS VS EstimatesMIST Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 2 -2

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for MIST. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for MIST. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
MIST Price Earnings VS Forward Price EarningsMIST Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
MIST Per share dataMIST EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.5 -1

4.3 Compensation for Growth

MIST's earnings are expected to grow with 20.35% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y12.44%
EPS Next 3Y20.35%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for MIST!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

MILESTONE PHARMACEUTICALS IN

NASDAQ:MIST (2/21/2025, 8:00:01 PM)

After market: 2.146 +0.11 (+5.2%)

2.04

-0.02 (-0.97%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-12 2024-11-12/bmo
Earnings (Next)03-19 2025-03-19/amc
Inst Owners42.61%
Inst Owner Change-99.78%
Ins Owners0.66%
Ins Owner Change0%
Market Cap108.79M
Analysts80
Price Target10.88 (433.33%)
Short Float %0.94%
Short Ratio0.75
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)21.86%
Min EPS beat(2)15.96%
Max EPS beat(2)27.76%
EPS beat(4)3
Avg EPS beat(4)16.04%
Min EPS beat(4)-0.39%
Max EPS beat(4)27.76%
EPS beat(8)7
Avg EPS beat(8)12.93%
EPS beat(12)9
Avg EPS beat(12)10.4%
EPS beat(16)13
Avg EPS beat(16)20.28%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)4.07%
PT rev (3m)4.07%
EPS NQ rev (1m)0%
EPS NQ rev (3m)29.07%
EPS NY rev (1m)0%
EPS NY rev (3m)0.67%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 4.53
P/tB 4.53
EV/EBITDA N/A
EPS(TTM)-0.81
EYN/A
EPS(NY)-1.02
Fwd EYN/A
FCF(TTM)-0.6
FCFYN/A
OCF(TTM)-0.6
OCFYN/A
SpS0
BVpS0.45
TBVpS0.45
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -51.71%
ROE -178.11%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-64.49%
ROA(5y)-54.31%
ROE(3y)-160.67%
ROE(5y)-113%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 2.18
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 42.57%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 15.4
Quick Ratio 15.4
Altman-Z -4.64
F-Score3
WACC8.45%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)41.3%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%60%
EPS Next Y54.32%
EPS Next 2Y12.44%
EPS Next 3Y20.35%
EPS Next 5Y27.19%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year-100%
Revenue Next 2Y114.48%
Revenue Next 3Y281.33%
Revenue Next 5Y200.41%
EBIT growth 1Y28.67%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year38.16%
EBIT Next 3Y-4.88%
EBIT Next 5Y27.87%
FCF growth 1Y38.93%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y38.82%
OCF growth 3YN/A
OCF growth 5YN/A